Psychological Distress and Quality of Life in Families With a Germline CDKN2A Pathogenic Variant

被引:0
|
作者
Onnekink, A. M. [1 ]
Klatte, D. C. F. [1 ,2 ]
van Hooft, J. E. [1 ]
van den Berg, S. H. [1 ]
van Der Zwaan, S. M. S. [1 ]
van Doorn, R. [3 ]
Hinnen, S. C. H. [4 ,5 ]
Potjer, T. P. [6 ]
Bleiker, E. M. A. [6 ,7 ,8 ]
van Leerdam, M. E. [1 ,9 ]
机构
[1] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, Leiden, Netherlands
[2] Mayo Clin, Dept Gastroenterol & Hepatol, Jacksonville, FL USA
[3] Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands
[4] Leiden Univ, Dept Psychooncol, Med Ctr, Leiden, Netherlands
[5] Spaarne Gasthuis, Dept Med Psychol, Haarlem, Netherlands
[6] Leiden Univ, Med Ctr, Dept Clin Genet, Leiden, Netherlands
[7] Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, Amsterdam, Netherlands
[8] Netherlands Canc Inst, Dept Clin Genet, Amsterdam, Netherlands
[9] Netherlands Canc Inst, Dept Gastrointestinal Oncol, Amsterdam, Netherlands
来源
MOLECULAR GENETICS & GENOMIC MEDICINE | 2025年 / 13卷 / 02期
关键词
cancer surveillance; cancer worry; CDKN2A; genomic medicine; hereditary cancer syndrome; hereditary melanoma; hereditary pancreatic cancer; molecular genetics; psychological distress; quality of life; PANCREATIC-CANCER SURVEILLANCE; HOSPITAL ANXIETY; HEREDITARY CANCER; RISK; INDIVIDUALS; WOMEN; WORRY; QUESTIONNAIRE; PROGRAM; IMPACT;
D O I
10.1002/mgg3.70045
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
BackgroundIndividuals with a germline CDKN2A pathogenic variant (PV) have an increased lifetime risk of melanoma and pancreatic cancer. It is unknown whether the CDKN2A PV impacts quality of life (QoL). Therefore we aimed to assess QoL and psychological distress in families affected by the PV.MethodsThis cross-sectional study included confirmed carriers and those with a 50% likelihood of carrying the PV (at-risk carriers) under cancer surveillance who were invited to complete a one-time questionnaire. Both confirmed and at-risk carriers are offered skin surveillance, whereas only confirmed carriers aged 40 years or older can participate in pancreatic surveillance.ResultsIn total, 59/247 (24%) individuals under skin surveillance only (skin surveillance group) and 188/290 (65%) individuals under both skin and pancreatic cancer surveillance (pancreatic surveillance group) responded. In both surveillance groups, health-related QoL and general distress levels were within the general population norms. However, more than 40% of all study participants reported melanoma-related distress. Pancreatic cancer-related distress was experienced by 45% of the pancreatic surveillance group. Determinants of cancer-related distress were a first-degree relative with melanoma or pancreatic cancer, increased cancer risk perception, and poor general health perception. Over 80% of the participants felt that the benefits of cancer surveillance outweigh the disadvantages.ConclusionIn conclusion, confirmed and at-risk carriers of the CDKN2A PV under cancer surveillance experienced similar levels of QoL and general distress compared to the general population. However, cancer-related worry was substantial in this population. These findings can help identify individuals who may benefit from psychological support.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Screening for tumour suppressor p16(CDKN2A) germline mutations in Israeli melanoma families
    Yakobson, EA
    Zlotogorski, A
    Shafir, R
    Cohen, M
    Icekson, M
    Landau, M
    Brenner, S
    Usher, S
    Peretz, H
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 1998, 36 (08) : 645 - 648
  • [32] Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes
    Magnusson, Susanne
    Borg, Ake
    Kristoffersson, Ulf
    Nilbert, Mef
    Wiebe, Thomas
    Olsson, Hakan
    FAMILIAL CANCER, 2008, 7 (04) : 331 - 337
  • [33] Relevance of germline mutations in CDKN2A gene in breast cancer families with associated history of melanoma.
    Ganguly, A
    Godmilow, L
    Palmer, S
    Ganguly, T
    AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A21 - A21
  • [34] Germline copy number variations in melanoma families with/without CDKN2A/CDK4 mutations
    Yang, Xiaohong
    Shi, Jianxin
    Bennett, Hunter
    Burke, Laura
    Dagnall, Casey
    Burdette, Laurie
    Hicks, Belynda
    Tucker, Margaret
    Goldstein, Alisa
    CANCER RESEARCH, 2015, 75
  • [35] Germline CDKN2A mutation implicated in predisposition to multiple myeloma
    Dilworth, D
    Liu, L
    Stewart, AK
    Berenson, JR
    Lassam, N
    Hogg, D
    BLOOD, 2000, 95 (05) : 1869 - 1871
  • [36] CDKN2A germline mutations in individuals with cutaneous malignant melanoma
    Orlow, Irene
    Begg, Colin B.
    Cotignola, Javier
    Roy, Pampa
    Hummer, Amanda J.
    Clas, Brian A.
    Mujumdar, Urvi
    Canchola, Rebecca
    Armstrong, Bruce K.
    Kricker, Anne
    Marrett, Loraine D.
    Millikan, Robert C.
    Gruber, Stephen B.
    Anton-Culver, Hoda
    Zanetti, Roberto
    Gallagher, Richard P.
    Dwyer, Terence
    Rebbeck, Timothy R.
    Kanetsky, Peter A.
    Wilcox, Homer
    Busam, Klaus
    From, Lynn
    Berwick, Marianne
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (05) : 1234 - 1243
  • [37] Familial Melanoma, Pancreatic Cancer and Germline CDKN2A Mutations
    Goldstein, Alisa M.
    HUMAN MUTATION, 2004, 23 (06) : 630 - +
  • [38] Prospective risk of cancer in CDKN2A germline mutation carriers
    Goldstein, AM
    Struewing, JP
    Fraser, MC
    Smith, MW
    Tucker, MA
    JOURNAL OF MEDICAL GENETICS, 2004, 41 (06) : 421 - 424
  • [39] CDKN2A germline mutations in familial pancreatic cancer - Discussion
    Fernandez-Cruz, L
    Bartsch, DK
    ANNALS OF SURGERY, 2002, 236 (06) : 737 - 737
  • [40] Absence of Germline Epimutation of the CDKN2A Gene in Familial Melanoma
    van Doorn, Remco
    Zoutman, Willem H.
    Gruis, Nelleke A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (03) : 781 - 784